Where things have changed the most in the past year was the first-line indication. The KEYNOTE-024 trial was for patients with high PD-L1 expression [via] the IHC 22C3 pharmDX assay used for pembrolizumab. For those over 50% or at least 50%, patients were randomized to either get chemotherapy or pembrolizumab. There was superiority not just in survival, but in response, PFS, and OS with pembrolizumab in that setting. That rapidly changed practice.
abnormality, that is a better pathway to start with.
We have heard so much about pembrolizumab in recent months. What about some of these other PD-1/PD-L1 inhibitors?
With atezolizumab, we are waiting for the first-line data. It has its second-line approval and third-line approval for patients. If they have high PD-L1 expression, they are going to get pembrolizumab in the first-line setting but, in the second-line setting, atezolizumab is being used. It is something I am prescribing for my patients.
... to read the full story